Citation: | Wang Xiaoming, Shen Yuechun, Li Jun. Expression Level and Significance of CCL18 in Plasma of Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 694-697. DOI: 10.3971/j.issn.1000-8578.2012.06.020 |
[1] |
Leung SY,Yuen ST,Chu KM,et al.Expression profiling identifies chemokine (C-C motif) ligand 18 asan independent prognostic indicator in gastric cancer[J].Gastroenterology,2004,127(2):457-69.
|
[2] |
Schutyser E,Struyf S,Proost P,et al.Identification of biologically active chemokine isoformsfrom ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine inovarian carcinoma[J].J Biol Chem,2002,277(27):24584-93.
|
[3] |
Mantovani A.The chemokine system:redundancy for robust outputs [J].Immunol Today,1999,20(6):254-7.
|
[4] |
Busse D,Doughty RS,Arteaga CL.HER-2/neu (erbB-2) and the cell cycle [J].Semin Oncol,2000,27(6 Suppl 11):3-8.
|
[5] |
Miglietta A,Cayalli R,Bocca C,et al.Cellular uptake and cytotoxicity of solid lipidnanospheres (SLN) incorporating doxorubicin or paclitaxel [J].Int J Pharm,2000,210(1-2):61-7.
|
[6] |
Adema GJ,Hartgers F,Verstraten R,et al.A dendritic-cell-derived C-C chemokine thatpreferentially attracts naive T cells [J].Nature,1997,387 (6634):713-7.
|
[7] |
Guan P,Burghes AH,Cunningham A,et al.Genomic organization and biological characterization ofthe novel human CC chemokine DC-CK-1/PARC/MIP-4/SCYA18 [J].Genomics,1999,56(3):296-302.
|
[8] |
Tasaki Y,Fukuda S,Lio M,et al.Chemokine PARC gene (SCYA18) generated by fusion of two MIP-1alpha/LD78alpha-like genes[J].Genomics,1999,55(3):353-7.
|
[9] |
Shilling V,Jenkins V,Morris R,et al.The effects of adjuvant chemotherapy on cognition inwomen with breast cancer--preliminary results of an observational longitudinal study [J].Breast,2005,14(2):142-50.
|
[10] |
Budman DR.Dose and schedule as determinants of outcomes in chemotherapy for breast cancer[J].Semin Oncol,2004,31(6 Suppl 15):3-9.
|
[11] |
Charfare H,Limongelli S,Purushotham AD,et al.Neoadjuvant chemotherapy in breast cancer [J].Br J Surg,2005,92(1):14-23.
|
[12] |
Opdenakker G,Van den Steen PE,Laureys G,et al.Neutralizing antibodies in gene-defective hosts[J].Trends Immunol,2003,24(2):94-100.
|
[13] |
Struyf S,Schutyser E,Gouwy M,et al.CCL18 8/CCL18 is a plasma CC chemokine with increasedlevels in childhood acute lymphoblastic leukemia [J].Am J Pathol,2003,163(5):2065-75.
|
[14] |
Colcher D,Bird R,Roselli M,et al.In vivo tumor targeting of a recombinant single-chainantigen-binding protein[J].J Natl Cancer Inst,1990,82(14):1191-7.
|
[15] |
Wu AM,Senter PD.Arming antibodies:Prospects and challenges for immunoconjugates [J].NatBiotechnol,2005,23 (9):1137-46.
|
[16] |
Lin Y,Huang R,Chen L,et al.Identification of interleukin-8 as estrogen receptor-regulatedfactor involved in breast cancer invasion and angiogenesis by protein arrays [J].Int JCancer,2004,109(4):507-15.
|
[17] |
Lazennec G,Bresson D,Lucas A,et al.ER beta inhibits proliferation and invasion of breastcancer cells [J].Endocrinology,2001,142(9):4120-30.
|
[18] |
Cheng J,Lee EJ,Madison LD,et al.Expression of estrogen receptor beta in prostate carcinomacells inhibits invasion and proliferation and triggers apoptosis [J].FEBF Lett,2004,566(1-3):169-72.
|
[19] |
Lazennec G.Estrogen receptor beta,a possible tumor suppressor involved in ovariancarcinogenesis [J].Cancer Lett,2006,231(2):151-7.
|
[20] |
Ravdin PM,Chamness GC.The c-erbB-2 proto-oncogene as a prognostic and predictive marker inbreast cancer:a paradigm for the development of other macromolecular markers-a review [J].Gene,1995,159(1):19-27.
|
[21] |
Petit T,Wilt M,Velten M,et al.Comparative value of tumour grade,hormonal receptors,Ki-67,HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated withneoadjuvant anthracycline-based chemotherapy [J].Eur J Cancer,2004,40(2):205-11.
|